Moderate to Severe Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Moderate to Severe Diabetic Foot Infection (DFI) Market Outlook

Thelansis’s “Moderate to Severe Diabetic Foot Infection (DFI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Diabetic Foot Infection (DFI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Diabetic Foot Infection (DFI) Overview

Diabetic foot infection (DFI) is the most frequent reason for hospitalization and the primary cause of nontraumatic lower extremity amputation in individuals with diabetes mellitus. DFI is an infection affecting the soft tissues or bones below the malleoli. Clinical diagnosis of diabetic foot infections relies on identifying at least two typical signs of inflammation or purulence. These infections are categorized as mild, moderate, or severe. Typically, moderate infections (grade 3) extend more than 2 cm around the lesion, involve deep tissue abscesses, gangrene, or affect muscles, tendons, joints, or bones. In contrast, severe infections (grade 4) manifest as systemic infections with vital sign alterations like fever and hypotension. Peripheral artery disease contributes to diabetic foot infections, impairing blood flow and hindering wound healing in individuals with diabetes who may not initially perceive injuries. Consequently, moderate to severe foot infections become a heightened risk for this group. Most diabetic foot infections are polymicrobial, with aerobic gram-positive cocci, predominantly Staphylococcus species, being the most common pathogens. Diabetic foot infection can lead to the serious complication of osteomyelitis, necessitating surgical intervention. Diagnosis relies on clinical evidence, including purulent discharge from ulcers and classic signs of inflammation such as erythema, pain, tenderness, warmth, or induration. Additional indicators include unpleasant odor, necrosis, and wound healing failure despite optimal care. Prompt detection and proactive treatment of infections are crucial for managing diabetic foot complications. Moderate and severe diabetic foot infections may require intensive treatment and rehabilitation. The 5-year survival rate for individuals undergoing amputation due to diabetic foot ulcers (DFU) is believed to be less than 50%. Approximately 20% of diabetic foot patients with moderate or severe infections undergo partial foot amputation. Therefore, early detection and aggressive treatment are vital for individuals with diabetic foot problems, necessitating ongoing management, especially for moderate and severe infections.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Moderate to Severe Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034